URGN
Urogen Pharma Ltd. Health Care Pharmaceutical Preparations Russell 3000
$32.72Close
$1.6BMarket cap
$17.00 – $50.2952-week range
Nov 4, 2026Next report · before the open
Highlights
Strengths
- Leading the market RS 84 · stronger than 84% of stocks over 12 months
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Far from its high 35% below its 52-week high
- Distribution down-day volume 2.4× up-day volume over 50 sessions
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
35%
1wk
down 5.1%
price change
1mo
down 19.5%
price change
12-month return
up 65%
market up 11% ·
its own up 55%
F-score
2 / 9
Weak
Altman Z
-4.27
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 7.8%
EBIT / enterprise value
Cheaper than
9%
of the market · expensive
Revenue growth
up 21%
year on year
EPS growth
—
latest quarter
Sales growth
up 199%
latest quarter · +48 pts
ROE
—
return on equity
Free cash margin
down 148%
-$162.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profits not fully backed by cash
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- assets working less efficiently
- profitability improving
- reduced long-term debt
Trade setup
ATR%
5.5%
$1.78 a day · 2×ATR $29.15
RS
84 / 99
vs the universe
Trend
5 / 8
under the 150/200-day, under the 50-day, over 25% off the high
Relative volume
1.3×
vs 50-day average
Up/down volume
0.42
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$105.5M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 14.5% over the year, from 42m to 48m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 90.2% to 88.7%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+15% vs market2 sessions after results
Financials
- Gross 89%
- Net -140%
- Free cash -148%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $11.8M | $48.0M | $64.4M | $82.7M | $90.4M | $109.8M |
| Gross margin | 91% | 89% | 88% | 89% | 90% | 89% |
| Operating income | -$126.7M | -$92.3M | -$79.0M | -$65.5M | -$96.8M | -$124.9M |
| Net income | -$128.5M | -$110.8M | -$109.8M | -$102.2M | -$126.9M | -$153.5M |
| Net margin | -1089% | -231% | -171% | -124% | -140% | -140% |
| Earnings per share | — | -$4.96 | -$4.81 | -$3.55 | -$2.96 | -$3.19 |
| Free cash flow | -$107.1M | -$85.6M | -$87.8M | -$76.6M | -$97.1M | -$162.7M |
| Free cash margin | -908% | -178% | -136% | -93% | -107% | -148% |
| Cash | $52.9M | $44.4M | $55.4M | $95.0M | $172.0M | $110.7M |
| Long-term debt | — | $0 | $97.5M | $98.6M | $121.7M | $122.2M |
| Shareholders' equity | $96.4M | $8.4M | -$89.4M | -$65.2M | -$8.8M | -$105.5M |
| Shares outstanding | 22.17m | 22.46m | 23.13m | 32.49m | 42.23m | 48.35m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 10, 2025 | Annual ↗ | Dec 31, 2024 | 69d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
| May 13, 2024 | Quarterly ↗ | Mar 31, 2024 | 43d |
| Mar 14, 2024 | Annual ↗ | Dec 31, 2023 | 74d |
| Nov 14, 2023 | Quarterly ↗ | Sep 30, 2023 | 45d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 20, 2026 | Other events ↗ |
| Aug 5, 2026 | Results ↗ |
| Jun 23, 2026 | Holder rights changed · Director or officer change · Shareholder vote ↗ |
| Jun 2, 2026 | Other events ↗ |
| May 6, 2026 | Results ↗ |
| Mar 2, 2026 | Results ↗ |
| Mar 2, 2026 | Material agreement · New obligation ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 27, 2025 | Director or officer change · Shareholder vote ↗ |
| Aug 7, 2025 | Results ↗ |
| Jul 3, 2025 | Director or officer change ↗ |
| Jun 13, 2025 | Other events ↗ |